Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | LATS1 | O95835 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27140815 | 0.91 | NAMPT (0.42) | NAMPTKDM4ALATS1CYP3A4NR1H2 | |
| SCHEMBL31751595 | 0.86 | NAMPT (0.43) | NAMPTKDM4ALATS1CYP3A4LATS2 | |
| SCHEMBL18848182 | 0.84 | NR1H2 (0.40) | NAMPTNR1H2CYP2C9 | |
| SCHEMBL27108521 | 0.83 | NR1H2 (0.46) | NAMPTNR1H2CYP2C9 | |
| Hydrochloric Acid SCHEMBL27147491 | 0.82 | NR1H2 (0.46) | NAMPTNR1H2CYP2C9 | |
| SCHEMBL31750681 | 0.80 | NR1H2 (0.46) | NAMPTNR1H2CYP2C9 | |
| SCHEMBL38662549 | 0.80 | LATS1 (0.44) | NAMPTKDM4ALATS1CYP3A4LATS2 | |
| SCHEMBL6508596 | 0.78 | NR1H2 (0.39) | NAMPTNR1H2 | |
| SCHEMBL17347544 | 0.77 | NR1H2 (0.38) | NAMPTNR1H2L3MBTL1CYP2C9 | |
| SCHEMBL17347582 | 0.77 | NR1H2 (0.41) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | NAMPT 4847/4885KDM4A 4714/4885LATS1 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.